Evogene to Present Its Pharma Discovery Achievements at BIO-Europe Spring 2026

Rhea-AI Summary

Evogene (NASDAQ: EVGN) will present pharma discovery achievements at BIO-Europe Spring 2026 in Lisbon, March 23–25, 2026. Evogene delegates Dr. Gabi Tarcic and Dr. Olga Nissan will deliver an oral presentation on March 24, 2026, 15:30 WET and are available for one-on-one meetings.

The presentation will highlight AI-driven small-molecule discovery and the company’s ChemPass AI™ platform enabling collaborative drug discovery with pharma and biotech partners.

News Market Reaction – EVGN

-0.36%

2 alerts

-0.36% News Effect

-7.1% Trough Tracked

-$26K Valuation Impact

$7M Market Cap

0.1x Rel. Volume

On the day this news was published, EVGN declined 0.36%, reflecting a mild negative market reaction. Argus tracked a trough of -7.1% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $26K from the company's valuation, bringing the market cap to $7M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference dates: March 23–25, 2026 Presentation time: 15:30–15:45 WET

2 metrics

Conference dates March 23–25, 2026 BIO-Europe Spring 2026 in Lisbon, Portugal

Presentation time 15:30–15:45 WET Drug Discovery and Development: Evogene session on March 24, 2026

Market Reality Check

Price: $0.8090 Vol: Volume 40,217 is well bel...

low vol

$0.8090 Last Close

Volume Volume 40,217 is well below the 20-day average of 583,942, indicating limited pre-news activity. low

Technical Shares at 0.7677 are trading below the 200-day MA of 1.18 and close to the 52-week low of 0.73 (vs. high 2.42).

Peers on Argus

EVGN is down 2.38% while peers ERNA (-5.28%), MBRX (-7.14%), MBIO (-3.57%), KZIA...

EVGN is down 2.38% while peers ERNA (-5.28%), MBRX (-7.14%), MBIO (-3.57%), KZIA (-1.43%) and LYRA (-0.13%) are also negative, but no peers appear in the momentum scanner and no same-day peer news is recorded.

Historical Context

5 past events · Latest: Mar 05 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 05	Earnings results	Negative	-6.2%	Full-year 2025 loss, lower revenues and inventory impairment despite strategic shift.
Feb 25	Strategy update	Positive	+4.6%	CEO letter outlining ChemPass AI™ focus and key partnerships in health and ag.
Feb 19	Earnings scheduling	Neutral	-5.6%	Announcement of timing for Q4 and 2025 results release and investor call.
Feb 17	Clinical collaboration	Positive	+1.7%	AI-driven collaboration with QUT targeting cisplatin resistance in NSCLC.
Feb 11	R&D collaboration	Positive	+1.0%	Collaboration on neutrophil-driven inflammatory diseases backed by a EUREKA grant.

Pattern Detected

Recent EVGN news has mostly led to modest price moves that align with the tone of each announcement, with one divergence around an earnings date scheduling release.

Recent Company History

Over the past month, Evogene has reported 2025 financial results, outlined a strategic refocus on its ChemPass AI™ engine, and announced multiple AI-driven collaborations in oncology and inflammatory diseases. Earnings updates on Feb 19 and Mar 5 saw shares decline despite the strategic shift and reduced loss, while partnership and strategy news on Feb 11, Feb 17, and a CEO letter on Feb 25 produced small positive moves. Today’s conference presentation fits into this ongoing effort to showcase ChemPass AI™ and attract partners.

Market Pulse Summary

This announcement highlights Evogene’s plan to present recent pharma discovery achievements and its ...

Analysis

This announcement highlights Evogene’s plan to present recent pharma discovery achievements and its ChemPass AI™ platform at BIO-Europe Spring 2026, reinforcing a strategy centered on AI-driven small-molecule design. In recent months, the company reported a narrowed 2025 net loss, divested non-core assets, and signed new collaborations in oncology and inflammatory diseases. Investors may watch for new partnerships, validation of ChemPass AI™ capabilities, and future financial updates as key milestones.

Key Terms

computational chemistry, generative AI, small molecules, drug discovery

4 terms

computational chemistry technical

"a pioneering company in computational chemistry specializing in the generative AI design"

Computational chemistry uses computer models and simulations to predict how molecules behave, how they interact, and what chemical reactions they may undergo. For investors, it matters because these virtual experiments can speed up drug discovery, materials design, and cost estimates—like using a wind tunnel for cars—helping companies reduce development time, lower research costs, and de‑risk projects before expensive lab work or clinical trials.

generative AI technical

"computational chemistry specializing in the generative AI design of small molecules"

Generative AI is a type of computer technology that can create new content, like text, images, or music, on its own. It’s important because it can produce realistic and useful material quickly, which could change how we create art, write stories, or even develop new products. Think of it as a smart robot that can invent and produce things almost like a human.

small molecules medical

"generative AI design of small molecules for the pharmaceutical and agricultural industries"

Small molecules are compact chemical compounds, often developed as medicines, that act by fitting into and altering the behavior of biological targets like proteins — think of them as tiny keys designed to turn specific locks in the body. For investors, they matter because small-molecule drugs are usually easier and cheaper to make, store and deliver (often as pills), have well-established regulatory pathways, and can offer scalable, potentially high-return commercial opportunities if they gain approval and market acceptance.

drug discovery medical

"enabling new opportunities for collaborative drug discovery with pharmaceutical and biotech partners"

The process of finding and creating new medicines, starting with identifying a biological problem and then searching for molecules that can fix it; this involves lab research, computer modeling and early tests to narrow thousands of candidates down to a few promising leads. Investors care because successful drug discovery can create patents, long-term sales and big gains but is costly and risky—like designing a key for a specific lock: most attempts fail, but a working key can be very valuable.

AI-generated analysis. Not financial advice.

Conference will be held at Lisbon, Portugal - March 23–25, 2026

REHOVOT, Israel, March 9, 2026 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a pioneering company in computational chemistry specializing in the generative AI design of small molecules for the pharmaceutical and agricultural industries, today announced it will be featured as a presenting company at the upcoming BIO-Europe Spring 2026 conference, being held on March 23-25, in Lisbon. Attending the conference on behalf of Evogene will be Dr. Gabi Tarcic, Chief Development Officer and Dr. Olga Nissan, VP Business Development.

At the conference, Evogene will present the latest achievements of its pharma division. Dr. Nissan will deliver an oral presentation highlighting the company's technological breakthroughs in AI-driven small-molecule discovery and optimization and will share insights into how ChemPass AI™ is enabling new opportunities for collaborative drug discovery with pharmaceutical and biotech partners.

Presentation Details:

Drug Discovery and Development: Evogene
Tuesday, March 24, 2026 | 15:30–15:45 WET | Theatre A

Dr. Tarcic and Dr. Nissan will both be available for one-on-one meetings at the conference, interested parties are encouraged to contact Evogene's investor or public relations team. 

To register as a participant of the conference see:
https://informaconnect.com/bioeurope-spring/

About Evogene Ltd.: 

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.

At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. By integrating AI-driven molecular design with experimental validation, ChemPass AI™ enables the efficient discovery of differentiated small-molecule candidates with improved probability of development success. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.

For more information, please visit www.evogene.com. 

Forward-Looking Statements: 

This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries use forward-looking statements in this press release when they discuss: Evogene's achievements of its pharma division, Evogene's technological breakthroughs in AI-driven small-molecule discovery and optimization, and the potential of ChemPass AI™ to enable new opportunities for collaborative drug discovery with pharmaceutical and biotech partners. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the aftermath of the recent war between Israel and each of (i) the terrorist groups, Hamas and Hezbollah, (ii) Iran, and (iii) other regional terrorist groups supported by Iran, and any potential destabilizations in Israel, neighboring territories or the Middle East region, and those risk factors contained in Evogene's reports filed with the applicable securities authority. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

Contact
ir@evogene.com
Tel: +972-8-9311901

Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/evogene-to-present-its-pharma-discovery-achievements-at-bio-europe-spring-2026-302708080.html

SOURCE Evogene

FAQ

When will Evogene (EVGN) present at BIO-Europe Spring 2026 and who will present?

Evogene will present on March 24, 2026 at 15:30 WET in Theatre A. According to the company, Dr. Olga Nissan will deliver the oral presentation and Dr. Gabi Tarcic will join, both available for one-on-one meetings during the conference.

What topics will Evogene (EVGN) cover in its BIO-Europe Spring 2026 presentation?

The presentation will focus on AI-driven small-molecule discovery and optimization using ChemPass AI™. According to the company, the talk will highlight technological breakthroughs and collaborative opportunities with pharmaceutical and biotech partners.

How can investors or partners arrange meetings with Evogene (EVGN) at BIO-Europe Spring 2026?

Interested parties can request one-on-one meetings by contacting Evogene's investor or public relations team. According to the company, Dr. Tarcic and Dr. Nissan will be available for scheduled meetings at the Lisbon conference.

Where and when is BIO-Europe Spring 2026 that Evogene (EVGN) will attend?

BIO-Europe Spring 2026 takes place in Lisbon, Portugal, from March 23–25, 2026. According to the company, Evogene's presentation is scheduled for March 24 in Theatre A at 15:30 WET.

What platform will Evogene (EVGN) highlight for drug discovery at the conference?

Evogene will highlight its ChemPass AI™ platform for generative AI design of small molecules. According to the company, ChemPass AI™ is enabling new collaborative drug-discovery opportunities with pharma and biotech partners.